مباشر

Clinical OMICsMayo Clinic’s REDMOD AI Doubles Early Detection Sensitivity in Pancreatic Cancer FierceBiotechIpsen scuttles liver disease candidates from $952M Albireo acquisition Endpoints NewsAmgen, AbbVie say IRA negotiations impacted Q1 sales Clinical OMICsAt-Home Blood Test Screens for Early Dementia Clinical OMICsGlioblastoma: Testosterone Supplements Linked to 38% Lower Risk of Death Endpoints NewsLilly plans new $4.5B manufacturing investment in Indiana Endpoints NewsBeOne culls five cancer programs and an autoimmune Phase 2 Endpoints NewsLonza looks to ride ADC wave with upcoming factory, workforce expansion FierceBiotechBipartisan PRIMATE Act aims to ban monkey imports to US Clinical OMICsEarly Glucagon Elevation Linked to MASLD in Type 2 Diabetes Clinical OMICsEpigenetic Markers Link Early-Onset Colon and Rectal Cancer to Specific Pesticide Clinical OMICsBlood Test Reads Cell Spatial Environment to Predict Immunotherapy Response

Endpoints News ٦ مايو ٢٠٢٦

BeOne culls five cancer programs and an autoimmune Phase 2

BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the d...

BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experimental medicines as ...